LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) reminds investors of the March 13, 2017 deadline to file a lead plaintiff motion in the class action filed by GPM on behalf of a class (the “Class”) of investors who purchased TG Therapeutics, Inc. (“TG Therapeutics” or the “Company”) (NYSE: TGTX) securities between September 15, 2014 and October 12, 2016, inclusive (the “Class Period”). TG Therapeutics investors have until March 7, 2017 to file a lead plaintiff motion.
TG Therapeutics is a biopharmaceutical company that focuses on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.
According to the Complaint filed in this Class Action, defendants made false and/or misleading statements regarding the enrollment practices for the Company’s GENUINE Phase 3 trial. TG Therapeutics allegedly failed to disclose to investors that it failed to implement a proper screening protocol in the trial enrolling sites, that the Company was not enrolling patients at the required rate for the study to be completed on time, and that it would never get 330 enrolled patients in the study.
If you purchased or otherwise acquired shares of TG Therapeutics during the Class Period you may move the Court no later than March 7, 2017 to request appointment as lead plaintiff. To be a member of the class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to firstname.lastname@example.org, or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.